Skip to main content

  • Home
  • About Us
    • Company Summary
    • Senior Management
    • The Board
    • Corporate Governance
      • Board Charter
      • Audit & Risk
      • Remuneration & Nominations
      • Code of Conduct
      • Continuous Disclosure
      • Risk Management
      • Shareholder Communication
      • Securities Trading
      • Board & Executive Evaluation
      • Diversity
  • Therapeutic Areas
  • Technology
    • MSCs
    • Immunotherapy
    • Sygenus
  • Product Pipeline
    • Pipeline Overview
    • Human Health
      • Progenza
      • Human Cancer Vaccine
      • Sygenus
    • Animal Health
      • CryoShot Canine
      • Kvax
    • Trials
  • Investors
    • ASX announcements
    • Financials
    • Analyst Coverage
    • Events & Presentations
    • Investor Relations Contact
    • Subscribe
  • News
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
  • Contact
  • Home
  • About Us
    • Company Summary
    • Senior Management
    • The Board
    • Corporate Governance
  • Therapeutic Areas
  • Technology
    • MSCs
    • Immunotherapy
    • Sygenus
  • Product Pipeline
    • Pipeline Overview
    • Human Health
    • Animal Health
    • Trials
  • Investors
    • ASX announcements
    • Financials
    • Analyst Coverage
    • Events & Presentations
    • Investor Relations Contact
    • Subscribe
  • News
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
  • Contact
  1. Home
  2. About
  3. News
  4. Article

Presentation on Japan First Strategy at Ord Minnett

Wednesday, 1 November 2017
Share
© 2018 Regeneus Ltd | Privacy | Terms of Service